Aptahem (APTA) Q2 2026 earnings summary

Executive summary

• Focused on advancing Apta-1 through strategic development and cost discipline amid a challenging financing climate.

• Strengthened manufacturing platform with improved purity and efficiency for Apta-1, supporting future clinical development and partnerships.

• Entered a commercial partnership agreement with Jarlen Capital for out-licensing opportunities post-period.

Financial highlights

• Operating income for Q2 2026 was 342 KSEK, down from 816 KSEK year-over-year; H1 2026 was 916 KSEK, down from 1,453 KSEK.

• Result after financial items for Q2 2026 was -1,351 KSEK (vs. -1,368 KSEK); H1 2026 was -2,743 KSEK (vs. -3,398 KSEK).

• Earnings per share for Q2 2026 was -0.05 SEK (vs. -0.08 SEK); H1 2026 was -0.11 SEK (vs. -0.20 SEK).

• Cash and cash equivalents at June 30, 2026, were 1,722 KSEK (vs. 1,781 KSEK).

• Equity ratio at June 30, 2026, was 98.66% (vs. 97.82%).

Outlook and guidance

• Continued focus on cost control and prioritizing value-creating activities for Apta-1.

• Actively seeking phase 2 collaborations with academic institutions for targeted studies in sepsis and related conditions.

• Strategy remains to advance Apta-1 toward patient studies and commercialization through clinical development, external validation, and strategic partnerships.